Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Sep 3, 2026
- Accession no.
- 0001636282-26-000107
- Filed
- Sep 3, 2026, 9:33 PM ET
- Trade date
- Sep 1, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.31M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | SSaleDisposed | −2,500 | $86.36 | −$215,900 | 565,040 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −8,400 | $87.15 | −$732,060 | 556,640 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −3,700 | $88.06 | −$325,822 | 552,940 | Direct | |
| Sep 1, 2026 | Common Stock | SSaleDisposed | −400 | $89.07 | −$35,628 | 552,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.